

A novel in-frame deletion in *MEN1* (p.Ala416del) causes familial multiple endocrine neoplasia type 1 with an aggressive phenotype and unexpected inheritance pattern

ANNA SKALNIAK^{1,2}, GRZEGORZ SOKOŁOWSKI², AGATA JABROCKA-HYBEL^{1,2},
JAKUB PIĄTKOWSKI^{1,2}, MAGDALENA BIAŁAS³, ALEKSANDRA GILIS-JANUSZEWSKA^{1,2},
DOROTA PACH^{1,2} and ALICJA HUBALEWSKA-DYDEJCZYK^{1,2}

¹Department of Endocrinology, Jagiellonian University Medical College; ²Endocrinology Clinic, University Hospital;

³Department of Pathomorphology, Jagiellonian University Medical College, 31-501 Krakow, Poland

Received September 16, 2015; Accepted February 15, 2016

DOI: 10.3892/mmr.2016.5462

Abstract. The present study describes a family with multiple endocrine neoplasia type 1 (MEN1) caused by a previously undescribed in-frame deletion c.1246_1248delGCC (Ala416del) in the *MEN1* gene. Evidence for the pathogenic character of this mutation, which triggers an aggressive clinical outcome, is demonstrated. Aggregation analysis in the tested family was strongly suggestive of causality of the detected mutation. This was supported by the analysis of LOH (loss of heterozygosity) in tumor-derived DNA and by computational analysis of the functional and structural implications of the mutation. Different phenotypic characteristics were identified among family members, which is typical for MEN1. Additionally, an unexpected disease inheritance pattern was observed in this kindred, in which either all or none of the siblings of one branch inherited the disease.

Introduction

Multiple endocrine neoplasia type 1 (MEN1) is an inherited disorder with high penetrance, which approaches 100% with increasing age (1). The disease occurs with a prevalence of 2-3 per 100,000 in the population (2). It is predominantly characterized by tumors of the parathyroid glands, gastroenteropancreatic tumors, pituitary adenomas, adrenal adenomas, and neuroendocrine tumors of the thymus, lungs or stomach, as well as non-endocrine lesions (2). The expression in terms of tumor localization, age of onset and clinical aggressiveness, may vary even between affected members of the same family. The clinical

manifestations of MEN1 are associated with the products of secretion of the tumors rather than the primary sites or metastases, and often appear at a young age (3). Management of MEN1 is based on treatment or prevention of manifestations (4).

The syndrome is caused by inactivating mutations in the tumor suppressor gene *MEN1*, coding for the 615-amino acid protein menin (5).

MEN1 syndrome is inherited in an autosomal dominant manner, which means that a single inherited mutation in the *MEN1* gene predisposes to somatic loss of heterozygosity (LOH) during a patient's lifetime. However, only once LOH has occurred does the disease begin to develop. LOH predominantly occurs in the region at which a mutation was inherited by the patient. This alteration may occur in different tissues; however, a person bearing a single mutation in *MEN1* is certain to develop the disease. The location, as well as the order and age of MEN1 manifestations are unpredictable (3). The majority of *MEN1* mutations that have been found in affected families result in truncated forms of menin. However, no genotype-phenotype correlations have been proven (2).

In the present study, a kindred with a previously unreported in-frame deletion in the *MEN1* gene, with an inheritance that is unexpected for Mendelian diseases was described.

Materials and methods

Subjects and case history. A large Polish kindred was identified, in which 3 generations had MEN1 (Fig. 1). All features presented within the case history occurred prior to the commencement of the study, and all patients were enrolled during the treatment stage. The index patient (II-3) was enrolled into the study aged 50 with suspected MEN1. The patient underwent parathyroidectomy due to primary hyperthyroidism at the age of 20. Somatostatin-receptor scintigraphy showed pathological foci of tracer uptake in the right mesogastrium projecting at the small intestine loop, in the pancreatic tail and in both adrenal glands. An abdominal magnetic resonance imaging scan confirmed the pancreatic tail tumor with a size of 20x15x11 mm; a similar lesion sized 16x13 mm was found in the topography of the inferior duodenal flexure. These

Correspondence to: Mrs. Anna Skalniak, Department of Endocrinology, Jagiellonian University Medical College, 17 Kopernika, 31-501 Krakow, Poland
E-mail: anna.skalniak@uj.edu.pl

Key words: multiple endocrine neoplasia type 1, mutation, family, inheritance, in-frame deletion




Figure 1. Pedigree showing MEN1 in a family. The arrow indicates the index patient. Square, male; circle, female; white, healthy individual, mutation status not tested; checked pattern, healthy individual, Ala416del germline mutation absent; Black, MEN1-affected individual with Ala416del germline mutation detected. Grey, MEN1-affected individual, mutation status not tested; /, dead; N, no data on health status. MEN1, multiple endocrine neoplasia type 1.

results were classified as typical for neuroendocrine tumors. Ultrasound-guided fine-needle biopsy of the pancreatic tumor showed well-differentiated neuroendocrine neoplasm cells (NEN G2; Ki-67-3%). The patient did not consent to the proposed neuroendocrine pancreatic tumor surgery (distal pancreatectomy). The clinical course of the disease was stable with unchanging tumor size and low chromogranin A levels until December 2014 when biochemical progression was observed (CgA-180 nmol/l). The patient did not turn up for further examination.

For the two children of the index patient-III-3 and III-4 (enrolled for observation at age 24 and 22, respectively), clinical observation, as well as diagnostic tests were MEN1-negative.

Four of the index patient's siblings (II-2, II-4, II-5 and II-6) also had symptoms of MEN1. The fifth sibling (II-1) unexpectedly succumbed to mortality aged 24.

Their father (I-1) reportedly died at the age of 68 as a result of pancreatic head cancer. He also presented with gastric ulcers, and underwent gastric resection ten years prior to his death.

Case II-2 succumbed to hepatic encephalopathy at the age of 38. In the past, he had presented with calcium-phosphate disorder, potassium leakage and hepatitis type C. According to this, the patient probably suffered from Cushing's syndrome. Of his two sons, III-1 died a tragic death aged 15. The other (III-2) was enrolled in our clinic aged 26 after parathyroidectomy due to primary hyperthyroidism.

One of the surviving brothers (II-4) of the index patient (aged 46) was diagnosed with primary hyperparathyroidism, nephrolithiasis, tumors in both adrenal glands, and pancreatic cancer. Computed tomography (CT) revealed mild hyperplasia of adrenal glands. No typical changes for NET were observed in CT. He was qualified for parathyroidectomy, but did not appear at set appointments to continue therapy. The patient had four children: III-5 aged 22, III-6 aged 21, III-7 aged 19, and III-8 aged 8, none of the children presented with a clinical manifestation that indicated MEN1.

The other brother (II-5) of the index patient was enrolled in the study aged 34 with parathyroid adenoma and hyperparathyroidism, after acute pancreatitis and after 3 extracorporeal shock wave lithotripsy surgeries. During early puberty, the resection of a lipoma from the middle upper abdomen was performed. The patient did not consent to surgery

of the parathyroid gland. There are no data regarding the health status of the patient's two children (III-9 and III-10), aged 15 and 4.

The sister (II-6) of the index patient was enrolled aged 37 with diffuse cancer due to a neuroendocrine tumor, most probably from the pancreas, and also with recurrence of primary hyperparathyroidism. She also suffered from nephrolithiasis, euthyroid multinodular goiter and secondary diabetes. She succumbed to hepatic encephalopathy aged 37. Her only son (aged 11) was unavailable for enrollment in the present study.

All tested family members gave their written informed consent for genetic testing. In the case of juvenile members, additional consent was obtained from their legal caretakers. The research has been approved by the local Ethics Committee, (approval no. KBET/70/B/2013).

DNA isolation. Whole peripheral blood samples (2.6 ml) from each patient were collected into EDTA-coated tubes (Sarstedt, Nümbrecht, Germany). DNA was isolated with the QIAamp DNA Mini kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol.

A formalin-fixed paraffin-embedded (FFPE) post-operative parathyroid gland was obtained from the index patient. Seven sections, with a thickness of 10 μ m each, were cut from a region that contained ~70% cancerous tissue, as assessed by light microscopy (Olympus BX51 with 40x UPlanFLN eyepiece; Olympus Corporation, Tokyo, Japan), which involved the fixation of the material in formalin, which was then processed by the routine method and embedded in paraffin. Sections (4 μ m) were cut from paraffin blocks and stained with standard hematoxylin and eosin (H&E; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for histological examination. Corresponding paraffin cube containing tumor tissue was selected on the basis of a comparison with H&E slides. DNA from these sections was isolated using the NucleoSpin FFPE DNA kit (Machery-Nagel, Dueren Germany). As a negative somatic control, a mixture of two randomly selected healthy post-operative FFPE parathyroid glands (which were removed together with the thyroid during surgery for non-parathyroid associated reasons from patients unrelated to the tested family and negative for MEN1 syndrome) were used.

Table I. Primers used in polymerase chain reaction.

Amplified region	Primer designation	Primer sequence	Product length (bp)
Exon 2	2_F	5'-AACCTTAGCGGACCCTGG-3'	654
	2_R	5'-ATAACACCTGCCGAACCTCA-3'	
Exon 3	3_F	5'-CCCTTTCCCCATGTAAAGC-3'	322
	3_R	5'-GGTGGCTTGGGCTACTACAG-3'	
Exon 4	4_F	5'-CCTTTTCCTGGCTGTCATTTC-3'	264
	4_R	5'-CCCACAGCAAGTCAAGTCTG-3'	
Exons 5-6	5-6_F	5'-CTAAGGACCCGTTCTCCTCC-3'	322
	5-6_R	5'-CCTGCCTCAGCCACTGTTAG-3'	
Exon 7	7_F	5'-GGCATTTGTGCCAGCAG-3'	261
	7_R	5'-GGAAACTGATGGAGGGGAAG-3'	
Exon 8	8_F	5'-AGGTCCCTGGGGCTACC-3'	271
	8_R	5'-ATGGCCTGTGGAAGGGAG-3'	
Exon 9	9_F	5'-CCCTCTGCTAAGGGGTGAG-3'	293
	9_R	5'-AAAAGTCTGACAAGCCCGTG-3'	
Exon 10	10_F	5'-TCCTGGAGTTCCAGCCAC-3'	618
	10_R	5'-GAACATGGGCTCAGAGTTGG-3'	
External region ('ext')	1f	5'-ACCCAGAGCCAAGGTTCC-3'	79
	2r	5'-ATTTGCAGATGCCGTCGTAG-3'	
Inner region wild-type allele ('wt')	Ww1	5'-AGGACCCTGAGTGCTTCGC-3'	54
	2r	5'-ATTTGCAGATGCCGTCGTAG-3'	
Inner region mutant allele ('mut')	1f	5'-ACCCAGAGCCAAGGTTCC-3'	60
	Wm2	5'-GTAGAATCGCAGCAGGTĈGA-3'	

Ĉ indicates the additional mismatch that was introduced into the Wm2 primer in order to enhance mutant allele specificity.

Sequencing

Amplification of products for sequencing. The 9 coding exons of *MEN1* (according to transcript variant 1, RefSeq NM_000244.3; (ncbi.nlm.nih.gov/nuccore)) were sequenced for the index patient, her siblings and children, and only the one exon in which the mutation was found, for the remaining participants. For PCR, 25 μ l reaction mixtures with HotStarTaq polymerase (Qiagen) were set up for each exon according to the standard recommendations of the manufacturer. The mixtures contained 0.2 μ M each of the appropriate forward and reverse primer (Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland), and 100 ng DNA. Primers are listed in Table I. Reaction conditions: Initial denaturation at 95°C for 15 min; 35 cycles including denaturation at 95°C for 30 sec, annealing at 59°C for 30 sec, and elongation at 72°C for 30 sec; final elongation at 72°C for 10 min. Samples were amplified in a Mastercycler realplex2 (Eppendorf, Hamburg, Germany).

Product purification and visualization. The quality of the products was assessed by 2% agarose electrophoresis in TAE buffer (Tris base, Thermo Fisher Scientific, Inc.; acetic acid, Chempur, Piekary Slaskie, Poland; EDTA, Avantor Performance Materials Poland S.A., Gliwice, Poland) and visualized with ethidium bromide (Sigma-Aldrich, St. Louis, MO, USA). The remaining PCR products were purified with




Figure 2. Relative copy numbers, with the heterozygous blood-derived DNA of the index patient as a reference. Average values of 3 independent experiments. Error bar indicates the standard error. Grey bars, wild-type copy number; black bars, mutant copy number. CTRL blood, germline copy numbers in healthy family member (III-4). IP blood, germline copy numbers in the index patient (II-3). IP tissue, somatic copy numbers in tissue from the index patient. CTRL tissue, somatic copy numbers in a thyroid of two mixed non-MEN1 patients.

the QIAquick PCR Purification kit (Qiagen), according to the manufacturer's protocol.

Sequencing PCR. The sequencing PCR reaction mixture included 1.25 μ l BigDye Terminator v3.1 (Thermo Fisher




Figure 3. Comparison of wt (3U84) and mutated menin. Left, amino acids 1-460 of menin protein (disordered structure excluded); right, zoomed in image of the mutated region, indicated by black boxes. In the wild-type protein, alanine is positioned in an α -helix structure (pink helix, upper picture), whereas in the mutated protein with the Ala416 deletion *in silico* modelling reveals disruption of the structure (blue strand, lower picture). Modelled with SWISS-Model (8), visualized with Jmol (<http://www.jmol.org/>).

Scientific, Inc.), 0.16 μ M of the appropriate forward or reverse primer, and 20 ng of the appropriate purified product. PCR was conducted under conditions recommended by the manufacturer. Specifically, PCR was conducted in Mastercycler RealPlex2 (Eppendorf, Hamburg, Germany) under the following conditions: Initial denaturation at 96°C for 1 min; 25 cycles including denaturation at 96°C for 10 sec, annealing at 55°C for 5 sec and elongation at 60°C for 4 min.

Ethanol precipitation. To purify products after the sequencing PCR, 2 μ l of 1.5 M sodium acetate/250 mM EDTA buffer, pH >8.0 were added to 10 μ l of the reaction mixture. After pipetting, 80 μ l of 95% ethanol were added, the samples were centrifuged for 15 min at 10,000 x g, and the supernatant discarded. The pellets were washed with 75% ethanol and centrifuged for 2 min in 10,000 x g. After dissolving the supernatants, DNA pellets were left to air-dry, and dissolved in 20 μ l nuclease-free water (Ambion; Thermo Fisher Scientific, Inc.). The whole procedure was conducted at room temperature. The purified products were separated on the ABI3500 sequencer (Thermo Fisher Scientific, Inc.).

Sequence analysis. The obtained sequences were aligned to the reference NC_000011.10 with SeqScape software (version 2.7; Thermo Fisher Scientific, Inc.). After identification of an exon-shortening event, the overlapping sequence resulting from the heterozygous deletion was analyzed manually using FinchTV (version 4.0; Geospiza, Inc, Seattle, WA, USA).

Multiplex ligation-dependent probe amplification (MLPA). MLPA was performed with use of SALSA MLPA probemix P017-C1, lot C1-0711 (MRC-Holland, Amsterdam, the Netherlands). The reaction was performed according to the manufacturer's protocol, using 100 ng DNA. Results were analyzed with Coffalyser.net (version 131123; MRC-Holland; Amsterdam, Netherlands).

Testing for LOH. After an initial PCR with external primers, three quantitative PCRs per sample were performed-with external primers ('ext'), and with internal primers specific for the wild-type allele ('wt') or for the mutant allele ('mut'). Each sample was run in triplicate. Primer sequences are presented in Table I.

At the time of primer design it was assured that the tested patients and controls did not bear the rs2071313 polymorphism in germline material, in order to avoid lack of primer binding due to this change.

The 10 μ l real-time PCR mix contained 5 μ l RT 2X PCR Master mix SYBR-C (A&A Biotechnology, Gdynia, Poland), one of 4 successive ten-fold dilutions of the external-PCR product, and standardized amounts of primers: 6 μ M each for the 'wt' and the 'mut' reactions, and 3 μ M forward and 6 μ M reverse primer for 'ext'. The reaction was set on ice; the prepared samples were put into the heated thermal cycler. Reaction conditions were as follows: 40 cycles consisting of 95°C for 5 sec, 59°C for 10 sec, 72°C for 8 sec and 80°C for 15 sec; followed by a single step of 95°C for 15 sec. Fluorescence was measured after each 80°C step. A melting curve analysis step was added after the reaction. Each sample was run in triplicate. All reactions were run in the Mastercycler realplex2 (Eppendorf, Hamburg, Germany).

The comparative C_q method was used to evaluate the copy number in tested samples, with DNA from the index patient as a reference ('IP blood'), which contains 1 wt and 1 mut copy. Amplification efficiencies (E) were included into the normalized copy number ratio equation $E^{-\Delta\Delta C_q}$ (6). Average values and standard errors were calculated from three independent experiments.

Results

DNA analysis. A heterozygous in-frame deletion, c.1246_1248delGCC, was identified by sequencing the *MEN1* gene for the index patient, II-3. At the protein level, this leads to the deletion of alanine at position 416 (p.Ala416del). According

to available variation databases, accessed on August 24, 2015 through the *Genome Browser* at UCSC Genome Bioinformatics (7) and The Universal Mutation Database (8), the identified mutation has not been reported previously.

The index patient's two adult children, III-3 and III-4 (at that time aged 24 and 22), did not exhibit any clinical manifestation to suggest MEN1, and the absence of any variant in *MEN1* was confirmed by sequencing of the whole coding region.

Sequence analysis revealed the presence of the c.1246_1248delGCC mutation in the other affected family members, II-4, II-5, II-6 and III-2. This mutation was not found in any of the four asymptomatic children of patient II-4 (III-5, III-6, III-7 and III-8). MLPA was performed for all affected family members, revealing no copy number changes among any exon or exon part of the *MEN1* gene. (data not shown).

In order to confirm that the detected c.1246_1248delGCC mutation was causative of the disease in this family, the post-operative FFPE parathyroid tissue from the index patient (II-3) was analyzed for an additional, somatic *MEN1* gene-function disrupting event (LOH), which typically occurs as a large deletion in any region of the gene, but predominately on that region of the wild-type allele in which the germline mutation occurs on the other allele.

MLPA, although suggestive for a large deletion encompassing the region with the mutation, gave ambiguous results, most probably because of the poor quality of the DNA, reflected by a poor Coffalyser Analysis Score for those samples.

The numbers of wild-type and mutated alleles were determined by relative quantification. Average values of 3 independent experiments are shown in Fig. 2. As expected, in the blood sample obtained from a healthy family member (the index patient's daughter, 'CTRL blood') and in healthy parathyroid tissue ('CTRL tissue') the number of wild-type alleles was twice that of the index patient, and the mutated allele was absent. Results from the transformed parathyroid tissue obtained from the index patient ('IP tissue') revealed that the relative quantities of the wild-type and the mutated allele were 0.33 and 1.81, respectively. If the LOH is due to a copy loss without mutant allele duplication, these values represent ~double of the factual amounts as, in fact, there is only one remaining copy (the mutated) left in the sample. The finding of 0.33 wt copy numbers in the sample (where 0 wt copy numbers would typically be expected) may arise from the surrounding tissue, which may have a different number of wt copies, as FFPE slices containing ~70% tumor tissue were used for analysis.

In silico analysis of the mutation. In the wild-type protein, alanine-416 is located in an α -helix near the disordered structure of the menin protein. According to SWISS-MODEL prediction (9), the deletion causes a disruption of the N'-terminal end of this helix (Fig. 3). The tool *PROVEAN* marked this mutation as 'deleterious' with a score of -10.97 (10). According to *SIFT Indel*, the mutation is 'damaging' to the protein, with a confidence score of 0.894, which indicates that it affects a Pfam domain and that the deletion is not located in a disordered region (11). Indeed, *MEN1* is conserved in bilateria (pfam05053), and Ala416 is located in a highly conserved region of the protein (12).

Discussion

It has previously been demonstrated that genetically diagnosed patients with MEN1 present with biochemical changes 10 years prior to the signs and symptoms of the disease (13), and an earlier diagnosis would allow for more effective management of the disease. In addition, patients who do not harbor a *MEN1* mutation may be prevented from undergoing unnecessary examination and lifelong surveillance (14). However, predictive testing can be offered to family members only after the disease-causing nature of a variant has been unequivocally established (4). It is therefore of importance for the patients and their family to confirm the pathogenic character of their mutation in *MEN1*.

Large deletions and mutations at conserved donor and acceptor splice sites, or mutations which introduce a premature stop codon in the protein-coding region of *MEN1* (nonsense mutations and frameshift insertions or deletions) are explicitly predicted to be disease causing (4). In the case of any other variant, it has yet to be elucidated whether this is a pathogenic or a neutral change. The present study provides evidence that the in frame deletion c.1246_1248delGCC in the *MEN1* gene, which, at the protein level, leads to the deletion of alanine at position 416 in menin, is a disease causing mutation. In order to confirm this finding, the post-operative FFPE parathyroid tissue from the index patient (II-3) was analysed for LOH in the region of the *MEN1* gene. The analysis of this large kindred resulted in a further notable observation. In this family, either all or none of the siblings inherited the disease. Statistically, this is not impossible, but taking into account Mendelian inheritance patterns, this observation may be noteworthy.

The present study is of importance as it characterizes a newly discovered pathogenic mutation which may be useful for any researcher or physician that encounters the same mutation in another family or patient, but is unable to assess its pathogenic status. In order to obtain more information about the inheritance of this mutation, further investigations involving the partners of the affected patients are required. The assessment of environmental factor influence on the development of the disorder would also be beneficial, however, for a small group of patients, this kind of investigation may be difficult and have limited statistical power.

Acknowledgements

This study was supported by the Polish Ministry of Science and Higher Education (grant no. K/ZDS/003796). The authors would like to thank Dr Łukasz Skalniak for his assistance in experimental design. The authors would also like to thank the described family for their collaboration.

References

1. Falchetti A: Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): When and how. *F1000 Med Rep* 2: 14, 2010.
2. Lips CJM, Dreijerink KMA, van der Luijt RB, van Nesselrooij BPM and Höppener JWM: MEN1.pdf. In: *Genetic Diagnosis of Endocrine Disorders*, 1st edition. Weiss RE and Refetoff S (eds.) Academic Press: pp261-270, 2010.

3. Lemos MC and Thakker RV: Multiple endocrine neoplasia type 1 (MEN1): Analysis of 1336 mutations reported in the first decade following identification of the gene. *Hum Mutat* 29: 22-32, 2008.
4. Giusti F, Marini F and Brandi ML: Multiple Endocrine Neoplasia Type 1. In: *GeneReviews™*. Pagon R (ed.) NIH, 2012.
5. UniProt Consortium: Activities at the universal protein resource (UniProt). *Nucleic Acids Res* 42 (Database Issue): D191-D198, 2014.
6. Green MR and Sambrook J: Chapter 9. In: *Molecular Cloning: A Laboratory Manual*. Vol 2. 4th edition. CSH Press, pp631-654, 2012.
7. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D: The human genome browser at UCSC. *Genome Res* 12: 996-1006, 2002.
8. Bérout C, Collod-Bérout G, Boileau C, Soussi T and Junien C: UMD (Universal mutation database): A generic software to build and analyze locus-specific databases. *Hum Mutat* 15: 86-94, 2000.
9. Arnold K, Bordoli L, Knopp J and Schwede T: The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. *Bioinformatics* 22: 195-201, 2006.
10. Choi Y, Sims GE, Murphy S, Miller JR and Chan AP: Predicting the functional effect of amino acid substitutions and indels. *PLoS One* 7: e46688, 2012.
11. Hu J and Ng PC: SIFT Indel: Predictions for the functional effects of amino acid insertions/deletions in proteins. *PLoS One* 8: e77940, 2013.
12. Marchler-Bauer A, Zheng C, Chitsaz F, Derbyshire MK, Geer LY, Geer RC, Gonzales NR, Gwadz M, Hurwitz DI, Lanczycki CJ, *et al*: CDD: Conserved domains and protein three-dimensional structure. *Nucleic Acids Res* 41 (Database Issue): D348-D352, 2013.
13. Lairmore TC, Piersall LD, DeBenedetti MK, Dilley WG, Mutch MG, Whelan AJ and Zehnauer B: Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). *Ann Surg* 239: 637-645; discussion 645-647, 2004.
14. Lourenço DM Jr, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA, dos Santos MA, Montenegro FL, Machado MC and Toledo SP: The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. *Clinics (Sao Paulo)* 62: 465-476, 2007.